IP Verse

A Pharmaceutical Composition Having A Rapid Action - EP2805716

The patent EP2805716 was granted to Orexo on Sep 13, 2017. The application was originally filed on Sep 24, 1999 under application number EP14175085A. The patent is currently recorded with a legal status of "Revoked".

EP2805716

OREXO
Application Number
EP14175085A
Filing Date
Sep 24, 1999
Status
Revoked
Jan 3, 2020
Grant Date
Sep 13, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PATENTANWALTSKANZLEI CARTAGENA PARTNERSCHAFTSGESELLSCHAFT KLEMENTApr 30, 2018-ADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0324725
OPPOSITIONEP0144243
OPPOSITIONEP0324725
OPPOSITIONWO0016750
OPPOSITIONWO9826780
SEARCHEP0144243
SEARCHUS4229447

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- FARRAR ET AL., J. NATL. CANCER INST., (1998), vol. 90, no. 8, pages 611 - 616-
DESCRIPTION- G. SALA ET AL., PROCEED. INT. SYMP. CONTR. RELEASE. BIOACT. MAT., (1989), vol. 16, page 420-
DESCRIPTION- Pharmaceutical Dosage Forms: Tablets, MARCEL DEKKER, (1989), vol. 1, pages 354 - 356-
DESCRIPTION- SALA, G.E. ET AL., PROC. INT. SYMP . CONTR. RELEASE BIOACT. MAT., (1989), vol. 16, page 420-
OPPOSITION- Lachmann and Liebermann, The Theory and Practice of Industrial Pharmacy, 3rd ed., (19900000), page 221, XP055282837-
OPPOSITION- Liebermann et al., Pharmaceutical Dosage Forms: Tablets, 2nd ed., (19890000), vol. 1, pages 1 - 6, XP055387119-
OPPOSITION- Milo Gibaldi, Biopharmaceutics and Clinical Pharmacokinetics, 4th ed., (19910000), page 51, XP055282823-
OPPOSITION- Remington: The Science and Practice of Pharmacy, (19950000), vol. I, page 595, XP055282825-
OPPOSITION- Walter Lund, The Pharmaceutical Codex, (19940000), pages 770 - 771, XP055489784-
SEARCH- Anonymous, "Patient Information Leaflet - PATIENT INFORMATION SUBOXONE® (sub-OX-own)(buprenorphine HCl/naloxone HCl dihydrate, sublingual tablet) (C*)SUBUTEX® (SUB-u-tex)(buprenorphine HCl, sublingual tablet) (C*)Read", FDA - U.S. Food and Drug Administration, URL: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM191530.pdf, (20141001), XP002731222 [Y] 1-14 * the whole document *-
SEARCH- NYSTROM C ET AL, "THE USE OF ORDERED MIXTURES FOR IMPROVING THE DISSOLUTION RATE OF LOW SOLUBILITY COMPOUNDS", JOURNAL OF PHARMACY AND PHARMACOLOGY, JOHN WILEY & SONS LTD, LONDON; GB, (19860101), vol. 38, no. 3, ISSN 0022-3573, pages 161 - 165, XP009062597 [Y] 1-14 * the whole document *-
SEARCH- WESTERBERG M ET AL, "Physicochemical aspects of drug release. XVIII. The use of a surfactant and a disintegrant for improving drug dissolution rate from ordered mixtures", S.T.P. PHARMA SCIENCES, (1993), vol. 3, no. 2, ISSN 1157-1489, pages 142 - 147, XP009062599 [Y] 1-14 * the whole document *-
SEARCH- MCQUINN R L ET AL, "Sustained oral mucosal delivery in human volunteers of buprenorphine from a thin non-eroding mucoadhesive polymeric disk", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, (19950601), vol. 34, no. 3, doi:10.1016/0168-3659(95)00008-V, ISSN 0168-3659, pages 243 - 250, XP004037503 [Y] 1-14 * page 244, paragraph bridging - page 245 *
SEARCH- DEGION JEAN-JACQUES, "La buprenorphine (Subutex), nouveau traitement de substitution des heroinomanes", EUROPEAN PSYCHIATRY, & EUROPEAN CONGRESS OF THE WORLD PSYCHIATRIC ASSOCIATION; GENEVA, SWITZERLAND; APRIL 23-26, 1997, (1997), vol. 12, no. SUPPL. 2, ISSN 0924-9338, page 157S, XP002730539 [Y] 1-14 * the whole document *
SEARCH- FARRAR J T ET AL, "ORAL TRANSMUCOSAL FENTANYL CITRATE: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL FOR TREATMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS", JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, (19980415), vol. 90, no. 8, ISSN 0027-8874, pages 611 - 616, XP001058154 [A] 1-14 * the whole document *
SEARCH- BULLINGHAM R E S ET AL, "Sublingual buprenorphine used postoperatively: Ten hour plasma drug concentration analysis", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, (1982), vol. 13, no. 5, ISSN 0306-5251, pages 665 - 673, XP002730538 [Y] 1-14 * page 665, column left, paragraph 2 * * page 666, column left, paragraph 3 full *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents